Safety profile-hATTR-PN

HELIOS-A Safety and Tolerability1

Chart showing adverse reactions reported in at least 5% of patients treated with AMVUTTRA®Chart showing adverse reactions reported in at least 5% of patients treated with AMVUTTRA®

Adverse reactions reported in at least 5% of patients treated with AMVUTTRA.1

  • There were no drug-related discontinuations or deaths in patients treated with AMVUTTRA2
  • Injection site reactions occurred in 4% of patients and were mild and transient1,2
  • Of patients treated with AMVUTTRA, approximately 3% developed anti-drug antibodies1,2
  • There are no contraindications for AMVUTTRA1

Connect with a Rep

Speak with an Alnylam Representative to learn more about AMVUTTRA.

Connect with a rep

Starting Treatment

Get your patients started on AMVUTTRA.

Up next: Learn About Dosing & Administration

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

In a study of patients with hATTR-PN, the most common adverse reactions that occurred in patients treated with AMVUTTRA were pain in extremity (15%), arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).

In a study of patients with ATTR-CM, no new safety issues were identified.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Indications

AMVUTTRA® (vutrisiran) is indicated for the treatment of the:

  • cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.
  • polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information.

References

  1. AMVUTTRA Prescribing Information. Cambridge, MA: Alnylam Pharmaceuticals, Inc.
  2. Adams et al. Amyloid. 2023;30(1):18-26.